Two new chimeric flaviviruses were constructed from full-length cDNAs that contained tick-borne encephalitis virus (TBEV) CME or ME structural protein genes and the remaining genes derived from dengue type 4 virus (DEN4). Studies involving mice inoculated intracerebrally with the ME chimeric virus indicated that it retained the neurovirulence of its TBEV parent from which its pre-M and E genes were derived. However, unlike parental TBEV, the chimeric virus did not produce encephalitis when mice were inoculated peripherally, indicating a loss of neuroinvasiveness. In the present study, the ME chimeric virus (vME) was subjected to mutational analysis in an attempt to reduce or ablate neurovirulence measured by direct inoculation of virus into the brain. We identified three distinct mutations that were each associated independently with a significant reduction of mouse neurovirulence of vME. These mutations ablated (i) the TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site. In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBE pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence. The only conserved feature of the three attenuated mutants was restriction of virus yield in both simian and mosquito cells. Following parenteral inoculation, these attenuated mutants induced complete resistance in mice to fatal encephalitis caused by the highly neurovirulent vME.
TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site. In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBE pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence. The only conserved feature of the three attenuated mutants was restriction of virus yield in both simian and mosquito cells. Following parenteral inoculation, these attenuated mutants induced complete resistance in mice to fatal encephalitis caused by the highly neurovirulent vME.
Following the success in constructing full-length dengue type 4 virus (DEN4) cDNA that can be transcribed to produce infectious RNA (15) , cDNAs of chimeric tick-borne encephalitis virus/DEN4 (TBEV/DEN4) constructs were prepared, and RNA transcripts of these cDNAs were shown to be infectious for permissive simian cells (20) . Two new flaviviruses were recovered that contained TBEV capsid (C), membrane (M), and envelope (E) or ME structural protein genes with the remaining genes derived from DEN4. The chimeric TBE(ME)/DEN4 virus was investigated in more detail, and it was observed that TBE(ME)/DEN4 virus replicated more efficiently than DEN4 in simian cells, reaching a titer 1,000-fold higher than DEN4, but it grew to a titer 100-fold lower compared with DEN4 in mosquito cells. Evaluation of chimeric virus in mice revealed that chimeric TBE(ME)/DEN4 virus caused fatal encephalitis in suckling and adult mice following intracerebral (i.c.) inoculation, whereas adult mice inoculated with DEN4 remained free of disease and few suckling mice developed encephalitis. Thus, the chimeric virus retained the neurovirulence of TBEV from which its pre-M and E genes were derived. In contrast, unlike parental TBEV, TBE(ME)/DEN4 virus was not virulent when adult BALB/c mice were inoculated peripherally, indicating a loss of neuroinvasiveness. Mice inoculated peripherally with TBE(ME)/DEN4 virus were protected against subsequent intraperitoneal (i.p.) challenge with a lethal dose of TBEV.
Success in constructing a viable TBEV/DEN4 chimera that retains the protective antigens of TBEV but lacks the peripheral invasiveness of TBEV provides the basis for * Corresponding author.
pursuing the development of an attenuated TBEV vaccine. However, before this goal can be realized, additional modifications of the chimera must be achieved to ablate neurovirulence for the central nervous system as measured by direct inoculation of virus into the brain. Analysis of amino acid sequences of a variety of flaviviruses indicates that potential N-linked glycosylation sites in the pre-M, E, or NS1 glycoprotein vary in number and in position, although similarities are also found (22, 28) . The functional role that the carbohydrate moiety of these glycoproteins plays during viral replication and in the pathogenesis is not known. Studies on a number of other viral systems including orthoand paramyxoviruses indicate that proteolytic cleavage of the attachment glycoprotein which mediates membrane fusion is essential for viral replication and that there is a strict correlation of cleavage and pathogenesis (4) . Flavivirus pre-M also undergoes cleavage during the late stage of viral maturation. There is evidence demonstrating that flavivirus E glycoprotein is capable of mediating membrane fusion at a low pH and that this activity is blocked if cleavage of pre-M to generate M is inhibited (9, 10) . Upon addition of acidotropic agents, such as NH4Cl, to flavivirus-infected cells, viral assembly continues to take place despite the fact that cleavage of pre-M is inhibited. Pre-M-containing virions produced intracellularly are reported to be less infectious than the extracellular M-containing virus particles (23) .
Engineering defined mutations in the DEN4 or TBEV portion of the chimeric genome should ultimately yield mutants that lack mouse neurovirulence. In this study, several strategic mutations were introduced into the full-length TBE(ME)/DEN4 virus cDNA construct. Six mutant chimeric viruses were recovered from transfected simian cells and analyzed for the effect of these mutations on To analyze proteins produced by the parental chimera (hereafter designated vME) or mutant chimeric vME, vCME, or DEN4, we infected confluent LLC-MK2 cells in a 25-cm2 flask at a multiplicity of infection of 0.01 PFU per cell. Six days after infection, cells were incubated with L-[35S]methionine (100 ,uCi per well, >800 Ci/mmol; Amersham Corp.) in methionine-free Eagle's minimal essential medium for 4 h, rinsed with 1 ml of cold phosphate-buffered saline, and then lysed with 1 ml of RIPA buffer (1% sodium deoxycholate, 1% Triton X-100, 0.1 M NaCl, 0.1 M TrisHCl, pH 7.5). Lysates were incubated with TBEV-or DEN4-specific HMAF, DEN4 NS1-specific monoclonal antibody, 8E2-2 rabbit TBEV E-specific serum, or rabbit DEN4 pre-M, E, NS3, or NS5-specific serum overnight in RIPA buffer containing 0.1% sodium dodecyl sulfate (SDS). Antibody-antigen complexes were collected with excess Pansorbin beads (Calbiochem), and precipitates were washed three times with 0.5 ml of RIPA buffer containing 2% SDS and analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (14) .
Mouse neurovirulence of parental and mutant vME. To estimate the pathogenicity of DEN4, chimeric ME or CME virus, or mutants of chimeric vME, 6-week-old female BALB/c mice were inoculated i.c. with 0.1, 1, 10, 100, 1,000, or 10,000 PFU of virus in 0.03 ml of minimal essential medium-0.25% human serum albumin. Mice were observed for 31 days for symptoms of encephalitis or death. To evaluate neuroinvasiveness of DEN4, chimeric ME virus, or its mutants, 6-week-old female mice in groups of eight were inoculated (i) i.c. with 103 or 104 PFU of DEN4, chimeric vME, or one of its mutants in 0.03 ml diluted as above, or (ii) i.p. or intramuscularly (i.m.) with 104, 105, 106, or 107 PFU of virus in 0.10 ml of dilutant. Mice were observed for 28 days. To determine the protective efficacy and immunogenicity of parental and mutant ME viruses, five female adult BALB/c mice were inoculated i.p. or i.m. with 104 PFU of virus in 0.1 ml of minimal essential medium or i.c. with 10 PFU of virus in 0.03 ml of minimal essential medium 0.25% human serum albumin. Mice were observed for 21 days, and surviving mice were bled 22 days after inoculation to evaluate antibody response. Surviving mice were challenged i.c. at 25 days with 104 PFU of parental ME virus and observed for an additional 4 weeks.
RESULTS
Design of mutant viruses. We previously used DEN4 cDNA as a cloning vector to construct chimeric TBEV/ DEN4 viruses containing C-pre-M-E or pre-M-E genes of TBEV and showed that these chimeras were able to replicate in primate-derived LLC-MK2 and mosquito-derived C6/36 cells (20) . Studies of mouse neurovirulence revealed that the chimeric vME was able to induce protective immunity against fatal TBEV peripheral challenge in mice. However, the chimera retained the neurovirulence phenotype of its TBEV parent as assayed by i.c. inoculation. Site-directed mutagenesis with synthetic oligonucleotides was performed to introduce one or more defined mutations in the DEN4 NS1 or TBEV pre-M or E gene in order to produce vME mutants that could be evaluated for the effect of such mutations on mouse neurovirulence. The first set of mutations was designed to ablate potential glycosylation sites in the TBEV pre-M or E or DEN4 NS1 protein. As (Fig. 1) for mutation in either of the glycosylation sites. The NS1 product of both mutants migrated faster than the NS1 protein of parental vME. It appears that the NS1 product of vNS1(R979, I980) migrated slightly faster than the NS1 product of vNS1(I103, R904) ( Fig. 1 and 2) . The NS1 protein of vNS1(I03, R904) or vNS1(R979, I980) was sensitive to digestion by endoglycosidase H (endo H), or endoglycosidase F (endo F) as indicated by a 3-to 5-kDa reduction of estimated molecular mass (Mr) following the treatment (Fig. 2) dimers, we analyzed the NS1 immunoprecipitates of both NS1 mutants by PAGE with or without prior boiling (Fig. 3) . A protein band migrating at about 90 to 96 kDa predicted to be dimeric NS1 was detected in unboiled samples. However, following boiling, the complex dissociated to yield monomers of about 41 kDa, suggesting that only one carbohydrate chain is required for dimer formation.
The E proteins of vE(L434) and parental vME virus did not appear to differ in gel migration. Also, gel mobility of the E protein produced by mutant vE(L434) or parental vME did not differ following treatment with endo F or endo H (Fig. 4) ; both E products were sensitive to endoglycosidase digestion. This is surprising because, according to the published data, the TBEV E protein contains an asparagine-linked carbohydrate at the first glycosylation site (11, 25, 27) , and the mutation in vE(L434) should abolish this site. Thus, the glycosylation mutation of vE (L434) Thr, Asn-753-Pro-Thr, and Asn-383-His-Cys (21) . Possibly, one of these otherwise nonused glycosylation sites became available for glycosylation when the preferred glycosylation site was abolished. Also unexpected was the abnormal gel migration of the NS1 protein produced by vE(L434) ( Fig. 1  and 4 ). However, after endoglycosidase treatment, the NS1 protein of vE(L434) and parental vME exhibited the same gel mobility (Fig. 4) (Table 2 and Fig. 5 ). Replication of vME and vCME on C6/36 cells did not differ, nor was plaque size different. However, vCME produced smaller plaques than vME on LLC-MK2 cells, and similarly, the maximum yield of vCME at 6 days after infection was lower than that of vME in these cells. This indicates that vCME is more restricted in growth in mammalian cells than vME. With the exception of vE(G384, F387), mutant chimeric viruses produced plaques that were considerably smaller than those produced by vME on LLC-MK2 or C6/36 cells ( Table 2 ). Plaque size reduction of these mutants was more profound on LLC-MK2 cells than on C6/36 cells. Also, mutations that were introduced to disrupt glycosylation of pre-M, E, or NS1 or cleavage of pre-M reduced growth in cell culture (Fig. 5) . Similar to parental vME, each of the mutants replicated faster and attained a higher titer in simian cells than in mosquito cells. Compared with parental vME, the growth rate of vPreM(V206) and vE(L434) mutants was found to be reduced in both cell lines. Six days after cation. Compared with vME, the NS1 glycosylation site mutation in vNS1(I903, R904) also caused a greater reduction of viral growth than did the NS1 glycosylation site mutation in vNS1(R979, I980). Also, growth of vME and vPreM(D143, R144) in LLC-MK2 cells was similar. In contrast, the mutation introduced into vE(G384, F387) increased viral yield of the mutant virus in both cell lines. This mutant reached a titer about 60-fold higher on C6/36 cells than that attained by parental vME under the same conditions.
Mouse neurovirulence. In a previous experiment, vME did not cause encephalitis in mice when inoculated by a peripheral route at a dose of 103 PFU (20) . To test the possibility that a higher dose of vME may breach the blood-brain barrier and cause fatal encephalitis, we inoculated 6-weekold mice with a larger dose of vME, i.e., 104, 105, 106, or 107 PFU by the i.p. or i.m. route. While all eight mice succumbed to encephalitis between days 10 and 16 after i.c. inoculation of 10' PFU, mice inoculated i.p. or i.m. with up to 1,000-fold more virus remained healthy during the 28-day observation period. This indicates that unlike TBEV, which is highly pathogenic for mice by peripheral inoculation (i.p. 50% lethal dose [LD50] of TBEV for adult BALB/c mice is 14.2 PFU) (20), chimeric vME virus, even at a dose of 107 PFU, failed to produce central nervous system disease. This leads us to conclude that the neuroinvasiveness of vME for mice is greatly reduced. However, the chimera retains the neurovirulence phenotype of its TBEV parent when inoculated i.c.
To evaluate the effect of the various mutations on neurovirulence, we inoculated 6-week-old BALB/c mice in groups of eight i.c. with each mutant virus, in a calculated dose ranging from 0.1 to 10,000 PFU per animal and observed them for 31 days for signs of encephalitis and death. This experiment was performed twice for vE(L434) and vNS1(I903, R904), three times for vPreM(V206), and four times for vME and DEN4 in order to achieve a more accurate estimate of mouse neurovirulence. Minimal variation of mortality (0 to 15%) was observed in replicate experiments. The LD50 for each virus was calculated (7) , and the value was used as the basis for comparison of mouse neurovirulence. Mice inoculated with DEN4 did not develop encephalitis. The LD50 of vPreM(Dl43, R144), vNS1(R979, 1980), or vE(G3.4, F387) was significantly reduced compared with the LD50 of 20 PFU for the parental vME. The observed increase of neurovirulence was 20-, 6.6-, and 10-fold, respectively. The mean survival time for mice inoculated with these three mutants was shorter than that of mice given the same dose of vME, confirming that these mutants are highly virulent. In contrast, the calculated mouse neurovirulence of vNS1(I903, R904) and vCME was more than 10 times less than that of vME. Of greater interest was the finding that mutants vPreM(V206) and vE(L434) were more than 100 times less neurovirulent than vME. Those mutants showing reduction of neurovirulence also exhibited reduced growth in simian and mosquito cell culture (Table 2 and Fig. 5) . Two of the mutants, i.e., vPreM(D143, R144) or vE(G3. 4, F387) , that exhibited increased neurovirulence in mice replicated to higher titer in mosquito cells than did parental vME. However, increased growth was not observed in simian cells.
Antibody response and protective efficacy. The mouse encephalitis model was used to determine the protective efficacy of the vME mutants. (Fig. 6) Our present study identified three mutations that are each associated independently with a significant reduction of mouse neurovirulence of vME. These mutations ablate (i) the TBEV pre-M cleavage site, (ii) the TBEV E glycosylation site, or (iii) the first DEN4 NS1 glycosylation site. In contrast, ablation of the second DEN4 NS1 glycosylation site or the TBEV pre-M glycosylation site or amino acid substitution at two positions in the TBEV E protein increased neurovirulence. vME was previously shown to lack neuroinvasiveness. By this we mean the inability to spread from a peripheral site of inoculation to the central nervous system and thereby cause
